A Double Blind, Placebo-Controlled, Single Center, Randomized, Sequential, Ascending 14-Day Multiple Dose Study in Subjects With Acne Vulgaris to Evaluate the Safety, Tolerability and Preliminary Efficacy of B244 Delivered as a Topical Spray
Phase of Trial: Phase I/II
Latest Information Update: 13 Apr 2017
At a glance
- Drugs B 244 (Primary)
- Indications Acne vulgaris
- Focus Adverse reactions
- Sponsors AOBiome
- 13 Apr 2017 Results published in an AOBiome media release.
- 13 Apr 2016 Status changed from recruiting to completed.
- 25 Jun 2015 New trial record